The behavior of the anti-SmRNP SLE subset was not significantly different from that of normal controls and other SLE subsets with respect to CIMT in addition to antibodies directed against oxidized LDL, LDL, or LPL (Table 1, Figures 1–3). This evidence concerns the gene LPL and systemic lupus erythematosus.